Review Article

Mesenchymal Stem Cells for Cardiac Regeneration: Translation to Bedside Reality

Table 3

Ongoing clinical trials on MSCs: condition, intervention/dose, and followup in patients around the world (http://www.clinicaltrials.gov).

World ConditionInterventionTime framePhase/Status

Florida (USA)Chronic ischemic LV dysfunction secondary to MI10 and 20 intramyocardial injections of 2 million MSCs (low dose) or 20 million (high dose)/0.25–0.5 cm3 for a total of 20 million or 200 million cells, respectively6–18 monthsPhase I/II (unknown)
Chronic ischemic LV dysfunction and heart failure secondary to MITransendocardial injection of autologous human cells (bone marrow or mesenchymal). 40 million cells/mL delivered in either a dose of 0.25 mL/injection for a total of 100 million ×  10 injections or a dose of 0.5 mL/injection for a total of 200 million ×  10 injections6–18 monthsPhase I/II (unknown)
Chronic ischemic LV dysfunction secondary to MITransendocardial injection of autologous versus allogeneic MSCs. 40 million cells/mL delivered in either a dose of 0.5 mL/injection ×  1 injection for a total of 20 million, a dose of 0.5 mL/injection ×  5 injections for a total of 100 million, or a dose of 0.5 mL/injection ×  10 injections for a total of 200 million MSCs6–13 monthsPhase I/II (active)
Nonischemic dilated cardiomyopathyTransendocardial injection of autologous versus allogeneic MSCs. 20 million cells/mL delivered in a dose of 0.5 mL/injection ×  10 injections for a total of 100 million of MSCs6–12 monthsPhase I/II (active)

Maryland (USA)Chronic ischemic LV dysfunction secondary to MI10 and 20 intramyocardial injections of 2 million MSCs (low dose) or 20 million (high dose)/0.25–0.5 cm3 for a total of 20 million or 200 million of autologous human MSCs, respectively6–18 monthsPhase I/II (unknown)
Chronic ischemic LV dysfunction secondary to MITransendocardial injection of autologous versus allogeneic MSCs. 40 million cells/mL delivered in either a dose of 0.5 mL/injection ×  1 injection for a total of 20 million, a dose of 0.5 mL/injection ×  5 injections for a total of 100 million, or a dose of 0.5 mL/injection ×  10 injections for a total of 200 million MSCs6–13 monthsPhase I/II (active)

France (Europe)Chronic myocardial ischemia; LV dysfunctionTransendocardial intramyocardial injections of 60 million autologous MSCs30 days–2 yearsPhase I/II (active)

China (East Asia)ST-elevation MIIntracoronary human umbilical WJ-MSC transfer4 months–1 yearPhase II (active)

Korea (East Asia)Acute MIIntracoronary injection of single dose of autologous bone-marrow-derived MSCs (I million) cells/kg6 monthsPhase II (completed)

India (South Asia)ST-elevation acute MIA Single Dose of Intravenous infusion of Allogenic MSCs6 monthsPhase I/II (active)